Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T26327
(Former ID: TTDI01185)
|
|||||
Target Name |
Superoxide anion (SPA)
|
|||||
Gene Name |
NO-GeName
|
|||||
Target Type |
Clinical trial target
|
[1] | ||||
Disease | [+] 1 Target-related Diseases | + | ||||
1 | Dissociative neurological symptom disorder [ICD-11: 6B60] | |||||
UniProt ID |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
1 | OPC-14117 | Drug Info | Phase 1 | Neurological disorder | [2] | |
Mode of Action | [+] 1 Modes of Action | + | ||||
Modulator | [+] 1 Modulator drugs | + | ||||
1 | OPC-14117 | Drug Info | [1] |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Evaluation of superoxide scavenging activity of OPC-14117 by electron spin resonance technique. Free Radic Res Commun. 1991;15(4):223-30. | |||||
REF 2 | ClinicalTrials.gov (NCT00002148) Parallel Group, Placebo-Controlled, Tolerability, Safety, and Efficacy Study of OPC-14117 in HIV Dementia. U.S. National Institutes of Health. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.